Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital

Key Points

• Humacyte's stock received a "buy" rating from D. Boral Capital, with a target price of **$25.00**.
• The company recently reported a quarterly earnings per share of **($0.24)**, missing the consensus estimate of **($0.15)**.
• Despite mixed ratings from analysts, the stock currently holds a consensus rating of **"Moderate Buy"**, with an average price target of **$9.29**.

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $25.00 target price on the stock.

A number of other equities analysts have also weighed in on HUMA. Barclays assumed coverage on Humacyte in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $3.50 price target for the company. TD Cowen cut their target price on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Wall Street Zen lowered shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, August 17th. HC Wainwright cut their price target on Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Humacyte in a research note on Saturday, September 27th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $9.29.

Humacyte Stock Performance

NASDAQ:HUMA traded up $0.42 during midday trading on Monday, reaching $2.52. 7,620,277 shares of the company traded hands, compared to its average volume of 3,941,618. The firm has a market capitalization of $398.31 million, a price-to-earnings ratio of -5.57 and a beta of 1.89. The company has a fifty day moving average price of $1.78 and a 200 day moving average price of $1.96. Humacyte has a twelve month low of $1.15 and a twelve month high of $6.77. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. On average, analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 591,685 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura E. Niklason sold 591,685 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders have sold a total of 4,482,090 shares of company stock worth $7,466,382 over the last 90 days. Corporate insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in the company. Columbia Advisory Partners LLC bought a new position in shares of Humacyte in the 1st quarter valued at about $27,000. Lazari Capital Management Inc. bought a new position in Humacyte during the second quarter worth about $27,000. Prudential Financial Inc. acquired a new position in Humacyte during the second quarter worth approximately $28,000. Financial Advisors Network Inc. acquired a new stake in shares of Humacyte in the second quarter valued at approximately $28,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Humacyte during the 2nd quarter worth approximately $30,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.